Weekly Update: December 27, 2021
Here’s to a Happy, Healthy and Prosperous New Years.
Even though the Covid variants continue to cause disruption, the markets are saying that the future looks bright.
I guess there is a Santa Clause after all, hoping he got vaccinated….
Yahoo Finance 12-27-21
Stock market news live updates: S&P hits intraday record as stocks charge higher, building Santa Claus Rally momentum
The S&P 500 hit an intraday record at Monday’s open, gaining 1% as U.S. stocks pushed forward after the holiday weekend, keeping pace on a strong start to the typically-bullish end-of-year-run known to investors as the Santa Claus Rally.
All three major indexes were up heading into a quiet final week of 2021 amid lower trading volumes and light economic and corporate calendars. The S&P and Nasdaq each ticked up more than 1% during midday hours, while the Dow jumped 230 points.
“I’m actually very bullish on the market,” Defiance Investments co-founder & CIO Sylvia Jablonski told Yahoo Finance Live. “There’s low liquidity in the markets this week, but we’re finishing out pretty strong. I would expect next year to be even better.”
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
The Premier Operating System for Publicly Traded Companies
Track your investors’ buying and selling behaviors and use those insights to engage them across marketing channels.
Know who’s buying and selling and monitor trading in real time. Unlock your shareholders contact info and build full contact profiles on your shareholders, including emails, phone numbers, and social media accounts to engage them and target new investors through media campaigns.
To schedule a demo email me at email@example.com or call 727-459-7378
12-20-21 SRAX (NASDAQ: SRAX)
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms as well as manage the flow of such media distributions. SRAX will employ leading-edge analytical algorithms in order to maximize engagement. “Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign,” said Chris Bunka, CEO of Lexaria Bioscience. “Lexaria has made tremendous progress during 2021 and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors.”
12-5-2021Apollo Future Mobility Group (HKSE 860)
Greenridge Global Research Issues Update
WM Motors Becomes Largest Shareholder
WM Motors Becomes Largest Shareholder. Last week there were a number of transactions with AFMG’s shareholders and WM Motors, which resulted in WM Motors becoming the largest shareholder of 860, now holding 28.5% of the issued shares. The Ho family, which had been the largest shareholder, exchanged 815,000,000 shares and Agile Property [HK: 3383] exchanged its 794,386,000 shares at HK$0.68 per share for WM shares; Agile also led the recent Series D2 round of WM Motors. Li Ka Shing and Solina Chau exchanged the remainder for WM shares, however the decrease in their shareholding of 860 was less magnified as they participated in the convertible debt deal prior to the exchange, as detailed below. While no formal statements have been made about the change in largest shareholder, we view these transactions as a net positive for AFMG. It ties the Company to an established auto manufacturer with a great deal of excess production capacity, which Apollo could potentially use for its Apollo branded EVs in China, provides the potential for better pricing on components, and could result in WM working with AAT for ESO projects.
HK$163.8 Million Raised From Convertible Debt. In September, AFMG raised a total of HK$163.8 million from the issuance of three-year 9% notes convertible at HK$0.55 per share. Roughly half of the notes were purchased by Li Ka Shing, Solina Chau and Tony Ho. The proceeds will be used for continued investments in its operations, namely new vehicle development and expansion of the ESO business.
Series Of Product Showcases. AFMG had another successful showing at CIIE last month, followed up by a showcase at the Macau Grand Prix, with an invitation-only event in Hong Kong on December 9.
Operations & Model Update. We made a number of changes to the model, primarily related to the timeline for vehicle deliveries, the biggest of which was pushing out Project EVO and its large Revenue contribution to 2024. The Company appears to have settled into a defined vehicle release schedule, with the IE Roadster and EVO Track models to be released prior to the EVO. We note our estimates contain no Revenue from the EVision S, which could completely change the model with thousands of vehicles delivered annually, starting in 2024. We also note that 38.76 million options have expired since the end of the fiscal year.
Maintaining Rating & Target. We view the share exchanges with WM Motors to be a net positive as it could speed the time to market and reduce the cost to bring the Apollo EVision S to mass production. We continue to believe the Company is being substantially undervalued by the market, given the valuations standalone EV companies receive, which is just one part of AFMG. Given its broad product and service portfolio, which should turn profitable in 2022, we are reiterating our Buy rating and HK$1.50 target price on Apollo Future Mobility Group. Our target price is based on a P/E multiple of 25 times our fiscal 2023 Diluted EPS estimate of HK$5.79 cents, which falls just before the launch of the Apollo EVision S.
12-3-2021 CanB Corp (OTC CANB)
Greenridge Global Research Issues Update
Revenue Surges In Q3, Reverse Split Approved
Revenue Surges In Q3. Can B reported third quarter Revenue of $1.91 million, which surpassed the Company’s Revenue for all of 2020. The surge was related to the acquisitions of TWS and MCB, which added significant processing capacity, as noted in our initiation report. Gross Margins were strong at 71.7%. Operating expenses of $3.89 million were higher than expected related to acquisition and Reg A offering costs. Net Loss for the quarter was $3.23 million, or $0.11 per share.
Reverse Split Approved. Yesterday, the Company filed a Proxy notifying shareholders that the Board approved a reverse stock split, which could range between 1:2 and 1:15. A full shareholder vote was not required due to the voting rights on the Series A and Series D Preferred Shares. We expect this move was done in anticipation of an uplisting.
Model Update. Despite beating on the topline in Q3, we are leaving the remainder of our estimates in place and will wait to make adjustments based on Q4, which will be the first full quarter with all of the processing equipment owned and operated.
Maintaining Rating & Target. With no material changes to our model, third quarter results that beat our estimate, and a potential uplisting on the horizon, we are reiterating our Buy rating and $1.20 target price on Can B Corp. We expect that a full quarter of operating results in the fourth quarter will be significant in showing the Revenue and Earnings potential of the re-made Can B. Our target price is based on a P/E multiple of 20 times our fiscal 2023 Diluted EPS estimate of $0.06, discounted one year at 10%.
12-2-21 Perpetual Industries Inc. OTC (PRPI)
Perpetual Industries Launches 506(c) Series A Preferred Share Offering for Stage One of Its Cryptocurrency Mining Division Expansion Plan
Perpetual Industries seeks to raise $7 million from accredited investors interested in diversifying their investments in the fast-growing cryptocurrency mining industry with a Series A Preferred Share Offering
AUBURN, Ind. , Dec. 02, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Perpetual Industries Inc. (OTCMARKETS:PRPI) (“Perpetual” or the “Company”), a diversified research and development company of energy-efficient technologies and commercialization of niche products today announces that it will offer up to 140 shares of its Series A Preferred Stock at $50,000 per share for an aggregate offering amount of $7 million. The shares will be offered to accredited investors and institutional investors only pursuant to Regulation D, Rule 506(c) under the Securities Act of 1933, as amended (the “Securities Act”). Although general solicitation is permitted under Rule 506(c) offerings, purchasers must be accredited investors and meet certain Securities and Exchange Commission (“SEC”) verification requirements for validation of their “accredited investor” status.
12-1- 2021 Antibe Therapeutics Inc. OTC ATBF (TSXV:ATE)
Antibe Pivoting to Acute Pain Management for Otenaproxesul
On October 14, 2021, Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) provided an update on the development of otenaproxesul following a comprehensive review of the absorption, metabolism, and excretion (AME) study that was previously paused due to six patients experiencing liver transaminase elevations (LTEs) exceeding five times the upper limit of normal (ULN). The company has determined that the best path forward for otenaproxesul is in the management of acute pain, with an initial indication of postoperative pain.
11-18-21 Perpetual Industries Inc. OTC (PRPI)
Perpetual Industries Reports Solid Third-Quarter Financial Growth
AUBURN, Ind., Nov. 18, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Perpetual Industries Inc. (OTCMARKETS:PRPI) (“Perpetual” or the “Company”), a diversified research and development company of energy-efficient technologies and products, is pleased to announce its financial and operating results for the third quarter of 2021.
Third Quarter 2021 Highlights for the Period Ending Sept. 30, 2021:
- Gross revenues increased $5,142,718 in the nine months ending Sept. 30, 2021, over the same period in 2020
- Gross profits increased $2,869,103 in the nine months ending Sept. 30, 2021, over the same period in 2020
- Net income recorded of $566,676 in the three months ending Sept. 30, 2021, a growth of 443% over the same period in 2020
- Cash reported on a consolidated basis of $3,471,679, an increase of 489% over year ending December 2020.
- Total current assets recorded of $3,553,323, an increase of 450% over year ending December 2020.
11-01- 2021 Antibe Therapeutics Inc. OTC ATBF (TSXV:ATE)
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
Otenaproxesul’s acute pain clinical program set to begin early next quarter
– Ended quarter with a $60 million cash position
TORONTO, November 16, 2021–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2021.
“With the clinical program for post-operative pain slated to begin early next quarter and third-party commercial studies underway, the scientific and strategic review we initiated during the quarter will soon be yielding results,” commented Dan Legault, Antibe’s CEO. “Our goal is to rapidly deliver a safe and effective alternative for physicians, surgeons and patients who today must choose between GI-damaging NSAIDs and addictive, side effect-prone opioids. With a strong balance sheet and extensive safety and efficacy data on otenaproxesul already in hand, we are well-equipped to target one of the most intractable problems in healthcare.”
11-5-2021 CanB Corp (OTC CANB)
Can B Corp. Reports 316% Revenue Growth to a Quarterly Revenue Record of $1.9 Million for its Third Quarter 2021
HICKSVILLE, NY / ACCESSWIRE / November 5, 2021 / Can B Corp. (OTCQB:CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing and selling hemp derived cannabinoid products, today announced the Company’s financial results for the third quarter ended September 30, 2021 (“Q3 2021”).
Key Financial Highlights during Q3 2021
- Revenue increased 316% in 3rd quarter 2021 to $1.9 million compared to Q3 2020- (a trend expected to continue into subsequent quarters into 2023
- Gross profit increased 261% to $1.4 million compared to Q3 2020
- Total assets increased to 14.2 million
- Total stockholders’ equity increased to $5.7 million
11-1-2021Guangdong Land Holdings Limited (HKSE 0124)
Greenridge Global Equity Research announced:
We are terminating coverage of Guangdong Land Holdings Limited in order to focus on other areas of interest to our institutional clients. As a result our previous rating, estimates and target price should no longer be relied upon.
11-01- 2021 Antibe Therapeutics Inc. OTC ATBF (TSXV:ATE)
Antibe Therapeutics Outlines Plan for Otenaproxesul’s Acute Pain Program
TORONTO, November 01, 2021–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, is pleased to provide further detail on otenaproxesul’s development plan for acute pain indications. Further to its October 14th press release, Antibe has now identified timing for the program’s key regulatory and development milestones for post-operative pain, the Company’s initial acute indication for otenaproxesul.
“With otenaproxesul’s impressive 14-day efficacy and GI safety profile, which is ideally suited for acute pain, we are well-positioned to rapidly bring to market a novel and safe non-opioid analgesic,” commented Dan Legault, Antibe’s CEO. “From a commercial standpoint, we see the $13 billion post-operative pain segment as an ideal springboard to the much broader acute pain market. Combined with the lack of innovation in oral analgesics and the urgent global need for non-addictive alternatives, we expect otenaproxesul to be especially attractive to potential partners. And with the option of funding the entire Phase III program with our current cash position, Antibe has a unique opportunity to shift the treatment paradigm of acute pain.”
All kinds of buys in the hospitality Industry especially restaurant and bar properties
If you want to learn more about how to take advantage of opportunities created by the Covid crisis
Message me on Linkedin and check our latest commercial listings:
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
|December 27, 2021
COMPANY QUOTES, LISTINGS RESEARCH AND NEWS
Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News
Can B Corp (CANB) Profile News
Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News
Social Reality, Inc. (SRAX) Profile 02/05/19 News
Apollo Future Mobility Ltd. (HK 0860) Profile 2/23/2020 News
ValuEngine Weekly Report
By: Herb Blank
Ultra Dividend ETF’s
The last Edition of this column focused on Dividend ETFs, each of which had the word Dividend in its name. The analysis focused on identifying the best overall ETF for conservative dividend-oriented investors as an alternative core holding that had more than twice the dividend yield of the S&P 500 while collecting comparable, if somewhat lower total returns.
Our top pick was SCHD, the Schwab US Dividend ETF despite the fact that SDOG (the ALPS Sector Dividend Dogs) had a higher dividend, 3.5% as compared with 3.0%.
That said, there are investors who have reached a point in their lives where they are no longer interested in capital appreciation and are focused only on income. This column is intended for them because there are, in fact, ETFs that provide more income than any ETF with the word dividend in the title. Read Complete Report
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Want to learn more about ValuEngine? Our methods? Our history?
Check out our video presentation HERE
Black Swan Research Coverage and Subscription Service
Event Calendar Updates
Not Surprisingly many conference events are cancelled or postponed- but are now getting back in action.
Rocky Mountain Microcap Conference VIII.
November 3, 2021 conference at TopGolf in Centennial Colorado was a great success with a higher than normal turnout.
Check it out and watch the presentations at:
LD Micro Main Event
October 12-14 Los Angeles.
This conference was a great success
All presenting company video calls will be available to view for 3 months. Visit the event website to see all the presentations: https://ldmicrojune2021.mysequire.com/
Check the website for updates:
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update-
SMM Global Twitter Acct (Impressions last 30 days) 520
SMM Global Facebook Page (Reach last-30 days) 6,462
SMM Linkedin Pages (contacts) 1,100
SMM Youtube Channel (followers) 6
SMM Instagram Page * (followers) 11
Direct Email * 220,000